Challenges and strategies for moving patients to injectable medications.
University of Pittsburgh Diabetes Institute, School of Medicine, Pittsburgh, PA, USA. simineriol@upmc.edu
Linda
L
Siminerio
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D007267:Injections; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D010353:Patient Education as Topic; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use; D014688:Venoms / Q000008:administration & dosage / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D007328:Insulin; D010455:Peptides; D014688:Venoms; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide